Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Average Target Price of $36.25 According to Brokerages

Posted by Geri Gentry on Oct 31st, 2026

Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $36.25.

Several equities research analysts have recently issued reports on NVCT shares. Roth Capital increased their target price on shares of Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Weiss Ratings upgraded Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. HC Wainwright restated a “buy” rating and issued a $39.00 price target on shares of Nuvectis Pharma in a research note on Thursday, September 24th. UBS Group set a $33.00 price target on Nuvectis Pharma in a research note on Monday, July 6th. Finally, Loop Capital set a $40.00 price target on Nuvectis Pharma in a report on Tuesday, September 1st.

Read Our Latest Stock Report on Nuvectis Pharma

Nuvectis Pharma Price Performance

NVCT opened at $18.48 on Friday. The firm has a fifty day moving average price of $21.45 and a 200 day moving average price of $14.61. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $29.27. The stock has a market cap of $603.26 million, a P/E ratio of -14.11 and a beta of -0.24.

Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Equities analysts expect that Nuvectis Pharma will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Legal & General Group Plc acquired a new position in Nuvectis Pharma during the second quarter worth $31,000. Bank of America Corp DE purchased a new position in Nuvectis Pharma during the second quarter valued at $218,000. Avalon Trust Co acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at about $257,000. Deutsche Bank AG acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at about $310,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Nuvectis Pharma in the second quarter valued at about $676,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

(Get Free Report)

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.